At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 156 enrolled
Drug / intervention
Etrasimod +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of APD334 in Patients With Moderately to Severely Active Ulcerative Colitis
In Brief
A Phase 2 clinical trial evaluating Etrasimod and Placebo for Ulcerative Colitis. Completed, enrolled 156 participants across 134 sites in 21 countries.
Detailed Summary
The purpose of this study is to determine whether etrasimod is a safe and effective treatment for ulcerative colitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUlcerative Colitis
CountriesAustralia, Austria, Belgium, Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Latvia, Lithuania, New Zealand, Poland, Romania, Russia, South Korea, Spain, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartOct 2015
Primary CompletionFeb 2018
TodayJul 2026
First PostedMay 18, 2015
Enrollment StartOct 15, 2015
Primary CompletionFeb 14, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 11.1 years ago
Interventions
Etrasimoddrug
Placebodrug